Medical Developments International (MVP.AX) Akcie Kurz

Medical Developments International Kurz

ASX·UZAVŘENO
0,43
​
Trh uzavřen

Za posledních 19 let vzrostly tržby Medical Developments International o 9,6 % ročně a dosáhly 42,57 Mil. AUD. Zisk na akcii klesal o 7,0 % ročně za posledních 19 let. U Medical Developments International je čistá marže 1,5 % nahoru oproti -56,5 % před několika lety. Při dnešní ceně vychází dividendový výnos zhruba na 6,39 %. Výplatní poměr je kolem 491 % zisku. Konsenzuální 12měsíční cílová cena pro Medical Developments International je 0,86 AUD, asi nad cenu o 101,6 %. Z 5 analytiků jich 4 doporučuje nákup — celkový konsenzus je Koupit.

Cena akcie Medical Developments International

Tato data přes Eulerpool API

100 000 požadavků/měs. zdarma · bez karty

Obchodní model Medical Developments International a analýza akcií

Medical Developments International Ltd je australská společnost specializující se na vývoj a výrobu lékařských přístrojů a produktů. Společnost byla založena v roce 1971 uznávaným výzkumníkem a podnikatelem Markem Sullivanem a od té doby získala četná ocenění. Obchodní model společnosti vychází z výroby nouzových lékařských přístrojů a produktů nejvyšší kvality a účinnosti. Má tři hlavní obchodní segmenty: farmaceutické výrobky, lékařské přístroje a veterinární zdravotnictví.

Nejčastější otázky týkající se akcie Medical Developments International

The business model of Medical Developments International Ltd is focused on developing and commercializing innovative pharmaceutical products. With a strong emphasis on research and development, the company aims to improve healthcare by offering safe and effective medical solutions. Medical Developments International Ltd strives to collaborate with healthcare professionals and institutions to deliver high-quality and affordable medical products. Through its commitment to innovation and partnership, the company has established itself as a leading player in the healthcare industry, continuously working towards improving patient outcomes and overall healthcare delivery.

Medical Developments International Ltd primarily operates in the healthcare industry.

The main competitors of Medical Developments International Ltd in the market include companies such as Pfizer, Johnson & Johnson, and GlaxoSmithKline.

Medical Developments International Ltd is a leading Australian pharmaceutical company specializing in the development and distribution of innovative medical devices and drugs. Founded in 1971, Medical Developments International Ltd has consistently demonstrated a commitment to improving patient outcomes through advanced healthcare products. With a strong focus on research and development, the company has successfully introduced breakthrough solutions in the areas of pain management, respiratory care, and emergency medicine. Over the years, Medical Developments International Ltd has garnered a solid reputation for delivering high-quality and effective medical solutions to healthcare professionals worldwide.

Medical Developments International Ltd has achieved significant milestones since its inception. The company has successfully developed and commercialized innovative medical solutions, positioning itself as a global leader in emergency medical products. Notably, Medical Developments International Ltd has received regulatory approvals for their flagship product, Penthrox, across various countries, including the EU, UK, Australia, New Zealand, and Canada. The company has also forged partnerships with renowned distributors, enabling them to expand their market presence and increase sales. Additionally, Medical Developments International Ltd has continuously invested in research and development to enhance their product portfolio, ensuring they remain at the forefront of medical advancements.

Medical Developments International Ltd (MDI) is primarily present in several countries and regions. The company has a global footprint with significant operations in Australia, New Zealand, and the United States. As an internationally recognized healthcare company, MDI caters to a wide range of markets worldwide, including Europe, Asia, and the Middle East. With its innovative medical solutions and strong market presence, Medical Developments International Ltd continues to expand its reach to meet the growing demand for its products and services across various countries and regions.

Medical Developments International Ltd represents the values of innovation, patient care, and commitment to excellence. With a corporate philosophy centered around improving health outcomes, they strive to develop and provide high-quality medical solutions. By continually researching and investing in cutting-edge technology, Medical Developments International Ltd aims to revolutionize healthcare and create effective treatments for various conditions. Their commitment to integrity, accountability, and ethical practices makes them a trusted leader in the industry. With a focus on improving the well-being of patients, Medical Developments International Ltd is dedicated to delivering innovative solutions that enhance the quality of life for individuals worldwide.

Analytici aktuálně stanovují průměrnou cílovou cenu 0,86 AUD pro akcii Medical Developments International (medián: 0,86 AUD), tedy +101,6 % vůči poslední ceně. Konsensus vychází z 5 hodnocení analytiků.

5 analytiků aktuálně hodnotí akcii Medical Developments International: 4 doporučuje koupit, 1 držet a 0 prodat.

Při aktuálním kurzu se akcie Medical Developments International obchoduje za 0,26 EUR (0,43 AUD).

Akcie Medical Developments International (MVP.AX) je kótována na 2 burzách, mimo jiné: ASX (MVP.AX).

Medical Developments International Ltd is an Australian company that offers sustainable solutions in the field of lifesaving, pain relief, and inhalation therapy. The company develops, manufactures, and distributes inhalers, pain relief products, and medical devices. In the lifesaving sector, the company offers the emergency inhalator system Penthrox. This system is used in the treatment of acute pain and injuries such as bone fractures and burns. The Penthrox system is easy to handle and can be quickly deployed by paramedics and emergency physicians on site. This technology is ideal for the military, sports events, and other public gatherings. The company also offers a wide range of pain relief products. The pain reliever Green whistle is a sustainable, hydrogen-based analgesic used in pain therapy. It is easy to use, safe, and effective. The device is ideal for use in hospitals, pain therapy, and palliative care. Inhalation therapy is the company's third business area. The company offers a wide range of inhalation devices specifically developed for people with asthma or other respiratory diseases. With the nebulizer "Nebu-Tech," patients receive precise dosage of the medication, which effectively reaches the lungs. The company has also developed solutions for kindergarten and school medicine to improve the treatment of children and students with asthma. Medical Developments International Ltd places special emphasis on sustainability and environmental friendliness. The company invests in research and development of sustainable technologies and materials to provide eco-friendly products and services. The products are designed for long-term use and can be easily recycled. The well-being of the patient is also a priority in production. No animal components are used, and high standards of quality and safety are ensured. In summary, Medical Developments International Ltd offers a wide range of products that can be used to save lives, alleviate pain, and treat respiratory diseases. The company is focused on sustainability and environmental friendliness and places special emphasis on quality and safety. With the marketing of high-quality products, the company aims to improve the lives of its customers.

Tržby za Medical Developments International činí 42,57 Mil. AUD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.

Zisk za Medical Developments International činí 626 000,00 AUD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.

Poměr ceny k zisku (P/E) Medical Developments International je aktuálně 78,70. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Medical Developments International.

Poměr ceny k tržbám (P/S) Medical Developments International je aktuálně 1,16. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Medical Developments International.

Score kvality pro Medical Developments International je 5/10.

ISIN Medical Developments International je AU000000MVP2. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.

WKN Medical Developments International je A0BLXB. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.

Ticker Medical Developments International je MVP.AX. Symbol tickeru se používá k obchodování akcií Medical Developments International na burze.

Spravedlivá hodnotaTerminal
0,35 AUD
Nadhodnocení/PodhodnoceníTerminal
Férovně oceněno
Průmysl
Farmaceutika
Počet akcií
Zaměstnanci
Tržby na zaměstnance
654 892,31 AUD
Růst tržeb Ø5 let
Růst EBIT Ø5 let
Růst čistého příjmu Ø5 let
Webové stránky medicaldev.com
Země
Austrálie
Měna
AUD
Veřejná nabídka akcií
15. 12. 2003
ISIN
AU000000MVP2
CUSIP
Q5922T102
SEDOL
6717070
Tržní kapitalizace
52týdenní rozpětí
PEG
0,99
P/E poměr
P/E poměr 2027
31,48
P/E poměr 2028
11,18
P/E poměr 2029
6,16
P/E poměr 2030
3,04
P/S
P/S poměr
1,07
EV/EBIT
33,08
P/B ratio
0,85
ROE (návratnost vlastního kapitálu)
ROA (návratnost aktiv)
ROCE (návratnost použitého kapitálu)
ROIC (návratnost investovaného kapitálu)
1,09 %
Dividenda
Dividendový výnos
0,00 %
Odhadované dividend yield
12,78 %
Podíl výplaty
606,34 %
Růst dividend Ø5Y
-17,33 %
Dividend za rok
2
Dividenda vyplácena od
0 let
Dividenda nezměněna od
0 let
Dividenda zvýšena od
0 let
Srážková daň
30,00 %
Poslední aktualizace 22. 11. 2026 11:38

Medical Developments International Ticker

ASX · MVP.AXOTC · MDDVF

Medical Developments International FIGI

MVP:AU · BBG000CPBHP3MVP:AT · BBG000CPBJ97M5D:GR · BBG000R1N261M5D:GB · BBG000R1N4R4MVP:AH · BBG002F3HZW1MDDVF:US · BBG0046HJPP4MDDVF:PQ · BBG0046HJQ36MDDVF:UV · BBG0046HJQ54MVPAUD:X2 · BBG00JZ5K8H0MVPAUD:XB · BBG00JZ5K8J8MVPAUD:XH · BBG00JZ5K8L5MVPAUD:XF · BBG00JZ5K8N3